Reductions in Asthma Exacerbation-Related Hospitalizations and Emergency Department Visits in Patients with Severe, Uncontrolled Asthma Treated with Tezepelumab: Results from the Phase 3 NAVIGATOR Study

被引：0

作者：

Bourdin, A. ^{[1
]}

Menzies-Gow, A. ^{[2
]}

Chupp, G. ^{[3
]}

Israel, E. ^{[4
]}

Hellqvist, A. ^{[5
]}

Hunter, G. ^{[5
]}

Ambrose, C. S. ^{[6
]}

Ackert, J. Llanos ^{[7
]}

Colice, G. ^{[8
]}

Cook, B. ^{[6
]}

Corren, J. ^{[9
]}

机构：

[1] Univ Montpellier, CHU Montpellier, INSERM, CNRS,PhyMedExp, Montpellier, France

[2] Royal Brompton Hosp, London, England

[3] Yale Sch Med, New Haven, CT USA

[4] Brigham & Womens Hosp, Pulm & Crit Care Med Allergy & Immunol, 75 Francis St, Boston, MA 02115 USA

[5] AstraZeneca, BioPharmaceut R&D, Biometr Late Stage Dev Resp & Immunol, Gothenburg, Sweden

[6] AstraZeneca, BioPharmaceut Med, Resp & Immunol, Gaithersburg, MD USA

[7] Amgen Inc, Global Med Affairs, Thousand Oaks, CA USA

[8] AstraZeneca, BioPharmaceut R&D, Late Stage Dev Resp & Immunol, Astrazeneca, MD USA

[9] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

A1203

引用

页数：2